Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Conditions

• Breast Cancer
• Metastatic Breast Cancer
• Drug-Related Side Effects and Adverse Reactions
• Pharmacogenetic Variant

Interventions

• DRUG: Sacituzumab Govitecan
• DRUG: Trastuzumab deruxtecan
• DRUG: Datopotamab Deruxtecan

Sponsor

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental